Agilus Diagnostics withdraws IPO plans, says SEBI

Gurugram-based diagnostics company Agilus Diagnostics, earlier known as SRL, has withdrawn its initial public offering plan in the last week on February 12.

The Agilus Diagnostics IPO consisted of only an offer-for-sale (OFS) of 1,42,33,964 equity shares by the existing shareholders, with no fresh issue component.

International Finance Corporation, NYLIM Jacob Ballas India Fund III LLC, and Resurgence PE Investments were the selling shareholders in the OFS.

As per the processing status of draft offer documents published dated February 16, the capital market regulator SEBI said Agilus Diagnostics has withdrawn its public issue on February 12.

Agilus, one of India's largest diagnostics service providers with a network of 413 laboratories, had filed draft red herring prospectus with the SEBI on September 29, 2023.

As per the said DRHP, promoter Fortis Healthcare held 57.68 percent stake in Agilus Diagnostics, while the 42.32 percent shares were held by public shareholders.

NYLIM Jacob Ballas India Fund III LLC is the largest shareholder with 15.86 percent stake, Resurgence PE Investments 8.05 percent shares, and International Finance Corporation 7.61 percent stake at the time of filing of draft papers.

Meanwhile, the Asirvad Micro Finance IPO has been kept in abeyance by the SEBI. This the subsidiary of Manappuram Finance.